PROGRAM MENU

EDUCATIONAL PROGRAM

PRE-SUMMIT WORKSHOPS

SATELLITE SYMPOSIA


Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2026 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.


  Wed - Mar 18      Thu - Mar 19      Fri - Mar 20      Sat - Mar 21   

THURSDAY, MARCH 19

7:00 - 8:00 AM
SATELLITE SYMPOSIUM
A MEDICAL FORUM FOR EVIDENCE, EXPERIENCE, AND INTERACTIVE DIALOGUE ON CONTEMPORARY CONSIDERATIONS IN HEMOPHILIA CARE (SPONSORED BY SANOFI)
B113-114

Hemophilia care is entering a transformative era, with growing emphasis on how clinical approaches can support the individual needs and treatment goals of patients. Join leading experts and peers for a dynamic and educational program featuring interactive dialogue across a range of topics, including case-based scenarios, evolving management strategies, and the broader aspirations of people living with hemophilia. This forum will provide real-world perspectives and practical insights from clinical practice, fostering thoughtful, balanced discussion to support healthcare professionals in considering a range of evidence-based strategies as they collaborate with patients in todays changing therapeutic environment. Submit Pre Questions here: https://www. surveymonkey. com/r/XPRQLLR


ADVANCING HEMOPHILIA CARE THROUGH TFPI INHIBITION: CLINICAL EVIDENCE AND EMERGING REAL-WORLD EXPERIENCE WITH HYMPAVZI (MARSTACIMAB) (SPONSORED BY PFIZER INC)
B115-116

Non‑factor therapies continue to reshape the treatment landscape for hemophilia by offering novel approaches to rebalancing coagulation. Hympavzi (marstacimab), a subcutaneously administered anti‑TFPI therapy, represents an important new option informed by both robust clinical data and emerging real‑world experience. This symposium will explore the scientific rationale, mechanism of action, clinical trial evidence, and practical considerations surrounding the use of Hympavzi (marstacimab) in hemophilia management. Faculty will review the foundational science behind Hympavzi (marstacimab) and summarize key findings from the Phase 3 clinical development program. In addition, the session will feature a discussion with hematologists who have real‑world experience integrating Hympavzi (marstacimab) into clinical practice. Their perspectives on patient selection, breakthrough bleeds, surgical data, monitoring, and initial outcomes will provide attendees with practical insights into how Hympavzi (marstacimab) may be incorporated into the evolving therapeutic landscape of hemophilia care.


7:00 - 6:30 PM
EVENT/OTHER
REGISTRATION
Oregon Ballroom Lobby

8:15 - 9:45 AM
PLENARY SESSION
IS DEI DOA?
Chair/Organizer: Julie Jaffray, Anne Rose
Oregon Ballroom 201


8:15
WELCOME TO THSNA 2026.


8:30
MEDICINE DEI
BETHANY SAMUELSON BANNOW.


8:55
DEI IN HEALTHCARE ACCESS
KERI NORRIS.


9:20
CAREER DEI
DEE TERRELL.

9:45 - 10:30 AM
POSTERS/EXHIBITS/BREAK
POSTERS/EXHIBITS/BREAK (click to view)
Exhibit Hall A


A1. ANTICOAGULATION CLINICS


100
A QUALITATIVE STUDY OF WARFARIN SELF-MANAGEMENT IN THE UNITED STATES HEALTHCARE SYSTEM: INSIGHTS FROM PATIENT EXPERIENCES
SPENCER J. GILBERT1, 2, HEESEUNG HONG1, AUBREY E. JONES1, 2, SARA R. VAZQUEZ1, 2, GEOFFREY D. BARNES3, KATELYN W. SYLVESTER4, DANIEL M. WITT1, 2. 1University of Utah College of Pharmacy, Salt Lake City, UT, USA. 2University of Utah Health Thrombosis Service, Salt Lake City, UT, USA. 3University of Michigan, Ann Harbor, MI, USA. 4Brigham and Women's Hospital, Boston, MA, USA


A3. VASCULAR WALL BIOLOGY, ENDOTHELIAL PROGENITOR CELLS AND PLATELET ADHESION


101
LOW-DOSE PLASMA-DERIVED VON WILLEBRAND FACTOR CONCENTRATE FOR SURGICAL PROPHYLAXIS IN EHLERS-DANLOS SYNDROME WITH NORMAL VWF PROFILES AND DESMOPRESSIN CONTRAINDICATIONS
JOSEPH STANCO, SUCHITRA ACHARYA. Northwell Health, New Hyde Park, NY, and Cohen Childrena, Queens, NY, USA


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION


102
HEPARIN INDUCED THROMBOCYTOPENIA IN CARDIAC SURGERY PATIENTS- A NATIONAL INPATIENT SAMPLE DATABASE STUDY FROM 2016-2021
SRUTHI/P RAMANAN1, KALAIVANI BABU2, SRINISHANT RAJARAJAN2, YIN YUE3, DEEP SHAH1. 1AHN Cancer Institute, Allegheny Health Network, Pittsburgh, PA, USA. 2Department of Internal Medicine, Allegheny Health Network, Pittsburgh, PA, USA. 3Allegheny Health Network, Pittsburgh, PA, USA


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS


103
COAGULATION PARAMETERS AFTER ADMINISTRATION OF BT524, FIBRINOGEN CONCENTRATE FROM HUMAN PLASMA, FOR THE TREATMENT AND PROPHYLAXIS OF BLEEDING IN PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCY: AN OPEN-LABEL PHASE I/III STUDY
CLAUDIA DJAMBAS KHAYAT1, AMAL EL-BESHLAWY2, EMNA GOUIDER BELHADJALI3, ABDERRAHIM KHELIF 4, SONIA ADOLF5, WOLFGANG MIESBACH6, HEIKE BOEHM7, SILKE AIGNER7, SALOMON ABRAHA7, FABIAN BOHLAENDER7, JOERG SCHUETTRUMPF7, 8. 1Department of Pediatrics, Hotel Dieu de France Hospital Beirut, Saint Joseph University, Beirut, Lebanon. 2Pediatric Hospital CU, Egyptian Thalassemia Association, El Cairo, Egypt. 3Hospital Aziza Othmana, Tunis, Tunisia. 4Farhat Hached Hospital, Ibn El Jazzar Faculty of Medicine, Sousse University, Sousse, Tunisia. 5National Research Center, Pediatric Hematology Department, El Cairo, Egypt. 6Department of Hemostasis/Hemophilia Centre, Medical Clinic 2, University Hospital Frankfurt, Frankfurt, Germany. 7Biotest AG, Dreieich, Germany. 8Grifols, Barcelona, Spain


104
CLOTTING POTENTIAL OF A NOVEL MESOPOROUS BIOACTIVE GLASS ABSORBABLE AND ANTIMICROBIAL HEMOSTATIC AGENT
KEITH A. MOSKOWITZ1, 2, SCOTT JANIS2, EMILY ALHASSAN2, JOHN WALDO3, MARK TOWLER3, PEDRO ABRANTES4, VANESSA JOOSTE4, BRETT JANIS2. 1KA Bioscience Consultants, LLC, Westfield, IN, USA. 2DesiCorp Inc, Louisville, KY, USA. 3Missouri University of Science a Technology, Rolla, MO, USA. 4University of the Western Cape, Cape Town, South Africa


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


105
OUTCOMES OF MARSTACIMAB IN NORTH AMERICAN PARTICIPANTS WITH HEMOPHILIA A AND B WITHOUT INHIBITORS: SUBANALYSIS OF THE PHASE 3 BASIS TRIAL
ANJALI A1, PENGLING 2, JENNIFER 3, TRAVIS 3, ANDREW 4. 1Stead Family Department of Pediatrics, Carver School of Medicine, University of Iowa, Iowa City, IA, USA. 2Pfizer Inc, Cambridge, MA, USA. 3Pfizer Inc, New York, NY, USA. 4Pfizer Inc, Collegeville, PA, USA


106
EXPLORATORY ANALYSIS FROM HAVEN 1-4 TO FURTHER CONTEXTUALIZE INJECTION-SITE REACTIONS AMONG PEOPLE WITH HEMOPHILIA A RECEIVING EMICIZUMAB
MAYA BLOOMBERG1, KATHERINE EAKLE2, MARKUS NIGGLI3, CHRISTOPHE DHALLUIN3, LUCY LEE2, ELISE LIM2, SHANNON L. CARPENTER4. 1Sylvester Comprehensive Cancer Center, Miami, FL, USA. 2Genentech, Inc, South San Francisco, CA, USA. 3F. Hoffmann-La Roche Ltd, Basel, Switzerland. 4Childrena, Kansas City, MT, USA


107
IRON DEFICIENCY AND SYMPTOM BURDEN IN PATIENTS WITH HEAVY MENSTRUAL BLEEDING
MAHALYA GOGERLY-MORAGODA, MD1, SUPREET KAUR GORAYA, MPH, IBCLC2, 3, ALICE MA, MD, FACP2, 3, CALLIE BERKOWITZ, MD2, 3. 1Internal Medicine Residency Program, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA. 2Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA. 3Blood Research Center, University of North Carolina, Chapel Hill, NC, USA


108
PATIENT- AND CAREGIVER-REPORTED OUTCOMES WITH SUBCUTANEOUS MIM8 PROPHYLAXIS IN PEDIATRIC PATIENTS WITH HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS: PHASE 3 FRONTIER3 STUDY
GILI KENET1, MATTEO LUCIANI2, PAULA KJAPLLERSTRAPM3, RUBACN BERRUECO4, AMALIE RHODE HACGH NIELSEN5, JAY JAY THAUNG ZAW5, EMILY WATERS6, KARIN FIJN VAN DRAAT7, RYAN RODRIGUEZ6. 1National Hemophilia Center and Institute of Thrombosis a Hemostasis, Sheba Medical Center, Tel Aviv, Israel. 2Onco-Hematology, Cell and Gene Therapy and Bone Marrow Transplant Clinic Area, Bambino GesA¹ Childrena, Rome, Italy. 3Pediatric Hematology Unit, Hospital Dona EstefAcnia, ULS SApo JosAc, Lisbon, Portugal. 4Pediatric Hematology Department, Hospital Sant Joan de DAcu, Universitat de Barcelona, Barcelona, Spain. 5Novo Nordisk A/S, SAcborg, Denmark. 6Novo Nordisk Inc, Plainsboro, NJ, USA. 7Department of Paediatric Haematology, Emma Childrena, Amsterdam, Netherlands


109
MAINTAINING FACTOR VIII TOLERANCE IN PATIENTS WITH SEVERE HEMOPHILIA A ON EMICIZUMAB: A FOUR-PATIENT CASE SERIES
EMILY E MASON, AMY DUNN. Nationwide Children's Hospital, Columbus, OH, USA


111
INSIGHTS INTO EFFECTIVE IMMUNE TOLERANCE INDUCTION IN HEMOPHILIA A PATIENTS WITH INHIBITORS:NEW FINDINGS FROM THE INTERIM ANALYSIS OF THE MOTIVATE STUDY
ROBERT F. SIDONIO, JR. 1, CARMEN ESCURIOLA ETTINGSHAUSEN2. 1Associate Professor of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, USA. 2HZRM HAcmophilie Zentrum Rhein Main, Frankfurt, Germany


112
ALTERED BASELINE FIBRINOLYTIC ACTIVITY IN LUNG CANCER PATIENTS: A FUNCTIONAL ASSESSMENT USING PLASMA LYSIS TIME AND FIBRINOLYTIC MARKERS
ANUHA VELLANKI1, PRAKASH KEMPAIAH1, ALEXANDER POHLMAN1, 2, FAKIHA SIDDIQUI1, WALTER JESKE 1, DEBRA HOPPENSTEADT1, JEANINE WALENGA1, W. KEITH JONES1, JEAN AMIRAL1, JAWED FAREED1, ZAID ABDELSATTAR1. 1Loyola Univeristy Chicago, Maywood, IL, USA. 2University of Illinois Chicago College of Medicine, Chicago, IL, USA


A7. PATHOPHYSIOLOGY OF THROMBOSIS


113
THE POTENTIAL OF SILVER NANOPARTICLES AS ANTIBACTERIAL AGENTS IN THE MANAGEMENT OF VTE FOLLOWING PRE-ECLAMPSIA
MANASVI KONDAMUDI1, AARAV KESKAR1, ATUL LADDU1, JAWED FAREED2. 1Global Thrombosis Forum, Suwanee, GA, USA. 2Loyola University, Chicago, IL, USA


A8. ANTITHROMBOTIC THERAPY


114
AI-DRIVEN DYNAMIC PATIENT AVATARS WITH RECURRENT THROMBOSIS AND INHERITED THROMBOPHILIA: A SCALABLE SIMULATION TOOL FOR PHYSICIAN TRAINING AND HANDOFF
ANVI AGARWAL1, ASMI AGARWAL1, ELIJAH ELDRIM2, ANDREW PRIMOUS2, YANHUI GUO3, RUCHIKA GOEL4, 5, RICHARD SELINFREUND6. 1McNeese P4 (Physician Preparatory Pathway Program), SIU School of Medicine, Springfield, IL, USA. 2Medical Microbiology and Immunology, SIU School of Medicine, Springfield, IL, USA. 3Department of Computer Science, University of Illinois Springfield, Springfield, IL, USA. 4Division of Hematology/Oncology, Simmons Cancer Institute, SIU School of Medicine, Springfield, IL, USA. 5Department of Pathology, Johns Hopkins University, Baltimore, MD, USA. 6Departments of Medical Microbiology, Cell Biology and Immunology, and Medical Education, Springfield, IL, USA


115
QUANTIFYING INAPPROPRIATE ANDEXANET ALFA USE PRIOR TO INSTITUTIONAL POLICY REVISION: A REVIEW OF FIFTY CONSECUTIVE ADMINISTRATIONS
ALIFYA ALTAF LOKHANDWALA, FILIP SADURSKI, ROHIT SHARMA, MONIKA ONUSSEIT, ELLEN ARRINGTON, SARAH BENMIR, MOOSA ALHODA, ABDULRAHMAN ALYOUNES ALAYOUB, MISHEL PAPALI, MATTHEW BASCIOTTA. Department of Medicine, Salem Hospital, Mass General Brigham, Salem, MA, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


117
DEVELOPMENT AND IMPLEMENTATION OF A SCREENING TOOL TO REDUCE BLEED RISK ASSOCIATED WITH ANTIPLATELET USE IN ANTICOAGULATION CLINIC PATIENTS
MATTHEW J. DESCHEPPER, JENNIFER HARDMAN, MEGAN GALLAGHER, HANNAH BREIDENBACH, MICHELLE TE RONDE. Froedtert a the Medical College of Wisconsin, Milwaukee, WI, USA


119
CASE REPORT OF A PEDIATRIC PATIENT WITH CONGENITAL FACTOR VII DEFICIENCY (4%) USING HUMAN RECOMBINANT FACTOR VIIA EPTACOG-BETA AS SECONDARY PROPHYLAXIS
ASHLEY WEHRLE1, ANUJ KAUL1, CLAYTON KUBRICK1, NICOLETTA MACHIN1, 2, CRAIG SEAMAN1, 2, FREDERICO XAVIER1, 2. 1the Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA. 2University of Pittsburgh, Pittsburgh, PA, USA

10:30 - 11:30 AM
SHORT TALKS
SHORT TALKS - ANTICOAGULATION CLINICS IN ACTION: PRECISION, PROTECTION, AND PERSONALIZATION
Chair/Organizer: Daniel C. Malone, Dan Witt
Oregon Ballroom 203


10:30
EVALUATING THE INDIRECT INTERACTION BETWEEN GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS AND WARFARIN USING REAL-WORLD DATA
SPENCER J. GILBERT1, 2, 3, SARA R. VAZQUEZ1, 2, ALEXANDER MILLAR3, RAMKIRAN GOURIPEDDI3, JULIO C. FACELLI3, DANIEL M. WITT1, 2. 1University of Utah College of Pharmacy, Salt Lake City, UT, USA. 2University of Utah Health Thrombosis Service, Salt Lake City, UT, USA. 3University of Utah Department of Biomedical Informatics, Salt Lake City, UT, USA


10:42
A NOVEL APPROACH TO ESTIMATING THE RISK OF GASTROINTESTINAL BLEEDING FOR PATIENTS ON ORAL ANTICOAGULANTS AND OTHER MEDICATIONS INCLUDING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND ANTIDEPRESSANTS
DANIEL C. MALONE1, AINHOA GOMEZ-LUMBRERAS1, ABDELRAHMAN G. TAWFIK1, DANIEL M. WITT1, GUILHERME DEL FIOL2, THOMAS REESE3. 1Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA. 23Department of Biomedical Informatics, School of Medicine, University of Utah, Salt Lake City, UT, USA. 3Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA


10:54
VALIDATION OF THE DIOAC-GIB MODEL FOR PREDICTING GASTROINTESTINAL BLEEDING IN ANTICOAGULATED PATIENTS: COMPARISON TO THE ALFALFA MODELS FOR WARFARIN AND DOACS
ABDELRAHMAN G. MALONE1, DANIEL C. MALONE1, AINHOA GOMEZ. -LUMBRERAS1, DANIEL M. WITT1, GUILHERME DEL FIOL2. 1Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA. 23Department of Biomedical Informatics, School of Medicine, University of Utah, Salt Lake City, UT, USA


11:06
OPTIMIZING ANTICOAGULATION IN PREGNANT WOMEN WITH PROSTHETIC HEART VALVES: A PROSPECTIVE COMPARATIVE STUDY FROM A PHARMACIST-LED CLINIC IN PAKISTAN
GUL SAMA1, 2, ALI HAMZA1. 1A¹ Department of Healthcare Management, Faculty of Business Management Sciences, Concordia University Chicago, Chicago, Illinois, USA, Chicago, IL, USA. 2National Institute of Cardivascular Diseases, KARACHI, Pakistan. 3Department of pharmaceutical sciences, Faculty of Pharmacy Institute of Pharmaceutical sciences, Jinnah Sindh Medical university, Karachi, KARACHI, Pakistan


11:18
OVERCOMING BARRIERS TO WARFARIN PATIENT SELF-MANAGEMENT IN THE US HEALTHCARE SYSTEM (THSNATRAVEL AWARDEE)
DANIEL M. WITT1, 2, HEESEUNG HONG1, 2, AARON S. WILSON1, AUBREY E. JONES1, 2, SARA R. VAZQUEZ1. 2, SPENCER GILBERT1, 2, DANIEL C. MALONE1, NATHORN CHAIYAKUNAPRUK1, 3, JORDAN B. KING4, 5, GEOFFREY D. BARNES6, KATELYN W. SYLVESTER7, LINH CHAN8, THOMAS DELATE9. 1University of Utah College of Pharmacy, Salt Lake City, UT, USA. 2University of Utah Health Thrombosis Service, Salt Lake City, UT, USA. 3IDEAS Center, Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, UT, USA. 4University of Utah School of Medicine, Salt Lake City, UT, USA. 5Institute for Health Research kaiser Permanente Colorado, Aurora, CO, USA. 6University of Michigan, Ann Arbor, MI, USA. 7Brigham and Women's Hospital, Boston, MA, USA. 8Loma Linda Veterans Affairs Healthcare System, Loma Linda, CA, USA. 9Kaiser Permanente National Pharmacy, Aurora, CO, USA


SHORT TALKS - INSIGHTS INTO THROMBOSIS: RISK FACTORS, MECHANISMS, AND DIAGNOSTIC APPROACHES
Chair/Organizer: Rushad Patell, Kavya Balusu
Oregon Ballroom 201


10:30
IRON DEFICIENCY CAN INCREASE THE RISK OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED PATIENTS WITH POLYCYTHEMIA VERA: A NATIONWIDE ANALYSIS (THSNATRAVEL AWARDEE)
KAVYA BALUSU, PURVA SHAH, CANDRIKA D. KHAIRANI, PETER KOUIDES. Rochester General Hospital, Rochester, NY, USA


10:42
COMPARATIVE EFFECTIVENESS OF APIXABAN AND RIVAROXABAN FOR STROKE PREVENTION IN PATIENTS WITH OBESITY WITH ATRIAL FIBRILLATION: A RETROSPECTIVE COHORT STUDY
PEDRO LUIZ L. B. DANIELIAN1, URSULA M. A. DE MATOS2, SAMANTHA J. NEESON1, AARTI H. ASNANI1, PATRICIA TUNG1, RUSHAD PATELL1. 1Beth Israel Deaconess Medical Center, Boston, MA, USA. 2University of Connecticut School of Medicine, Farmington, CT, USA


10:54
FACTOR X DEFICIENCY DOES NOT FULLY RECAPITULATE THE EFFECTS OF PROTHROMBIN KNOCKDOWN ON PODOCYTOPATHY DURING PROTEINURIC GLOMERULAR DISEASE (THSNATRAVEL AWARDEE)
KAUSHIK MURALIDHARAN1, AMANDA WALLER1, KATELYN WOLFGANG1, MAYRA OSEGUERA1, EMAN ABDELGHANI2, BRITTNEY SPRUILL1, BRYCE KERLIN1, 3. 1Center for Clinical and Translational Research, Abigail Wexner Research Institute at Nationwide Childrens Hospital, Columbus, OH, USA. 2Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA. 3Faculty of Medicine at The Ohio State University, Columbus, OH, USA


11:06
DROSOPHILA MELANOGASTER POTENTIAL MODEL FOR THROMBOSIS
FAKIHA SIDDIQUI1, SYED MOHAMMAD OMER KHALID2, NUSRAT JABEEN3, MUSHTAQ HUSSAIN4, JAWED FAREED1. 1Department of Pathology and Laboratory Medicine, Health Science Division, Loyola University Chicago, Chicago, IL. 2Dow University of Health Science, Karachi. 3Department of Microbiology, University of Karachi, Karachi. 4Dow Fly Lab and Stock Center, Dow College of Biotechnology, Dow University of Health Sciences, Karachi


11:18
THROMBOPHILIA TESTING IN PATIENTS WITH CRYPTOGENIC STROKE
MEERA SRIDHARAN, EUGENE SCHARF, ANEEL ASHRANI, ANIMESH PARDANANI, RAJIV PRUTHI. Mayo Clinic, Rochester, MN, USA


SHORT TALKS - INTEGRATING GENETICS, IMMUNOLOGY, AND DIAGNOSTICS IN MODERN COAGULATION MEDICINE / FROM GENETIC VARIANTS TO CLINICAL PATHWAYS: EVOLVING INSIGHTS IN BLEEDING AND THROMBOTIC DISORDERS
Chair/Organizer: Dawn Rotellini, Tomasz Kaminski
Oregon Ballroom 204


10:30
NEUTROPHIL-DEPENDENT INTERFERONOPATHY PROMOTES JOINT DAMAGE IN HEMOPHILIA.
TOMASZ KAMINSKI1, NICHOLAS SWENDROWSKI1, MARGARET V. RAGNI2, LYNN MALEC1, 3, PRITHU SUNDD1, 4. 1Thrombosis and Hemostasis Program, Versiti Blood Research Institute, Milwaukee, WI, USA. 2Department of Medicine, Division of Hematology, University of Pittsburgh, Pittsburgh, WI, USA. 3Departments of Medicine and Pediatrics, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA. 4Department of Medicine (Hematology and Oncology), Medical College of Wisconsin, Milwaukee, WI, USA


10:42
THE MEXICAN AMERICAN RESTRICTED ARG500LEU F2 VARIANT PROTHROMBIN-RGV ENCODES THE ZYMOGEN OF AN ANTITHROMBIN-SENSITIVE HYPOCOAGULABLE THROMBIN THAT LIKELY PROTECTS AGAINST VENOUS THROMBOEMBOLISM (VTE)
HENRY J. MEAD1, VINCENT P. DIEGO2, 3, MARCIO A. ALMEIDA2, 3, LUIS PENA MARQUEZ2, AFSHIN AMERI4, JUAN M. PERALTA2, 3, LAURA ALMASY11, HARALD H. GORING2, 3, MICHAEL RECHT5, 6, JOANNE E. CURRAN2, 3, KEVIN R. VIEL3, MIGUEL A. ESCOBAR7, 8, TAMMUELLA CHRISENTERY-SINGLETON9, 10, SARAH WILLIAMS-BLANGERO2, 3, JOHN BLANGERO2, 3, TOM E. HOWARD2, 3. 1Haplogenics, Brownsville, TX, USA. 2South Texas Diabetes and Obesity Institute and Department of Human Genetics, College of Sciences, Brownsville, TX, USA. 3Histonis, Portsmouth, NH, USA. 4Department of Pediatrics, Division of Hematology and Oncology, Georgia Health Sciences University, Augusta, GA, USA. 5Yale Center for bleeding and Clotting disorders, New Haven, CT, USA. 6, Yale University School of Medicine, New Haven, CT, USA. 7Division of Hematology and Oncology, Department of Medicine, University of Texas Health Science Center, Houston, TX, USA. 8Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA. 9American Thrombosis a Hemostasis Network, Hickory, NC, USA. 10Ochsner Clinic Foundation, New Orleans, LA, USA. 11Department of Biomedical and Health Informatics, Lifespan Brain Institute, Philadelphia, PA, USA


10:54
FACTOR VIII INHIBITOR KINETICS AND REAGENT COMPOSITION UNDERLIE FALSE-POSITIVE LUPUS ANTICOAGULANT PATTERNS IN ACQUIRED HEMOPHILIA A
HAMISH NICOLSON1, 2, STEVEN WONG1, 2. 1Providence Health Care, St. Paula, Vancouver, BC, Canada. 2Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada


11:06
INCREASING THE TIMELINESS OF SURGERY PLANDOCUMENTATION FOR PATIENTS WITH BLEEDING DISORDER-A QUALITY IMPROVEMENT PROJECT (THSNATRAVEL AWARDEE)
AMBER PRUETT1, VILMARIE RODRIGUEZ1, 2, CHARMAINE BIEGA1, MICHELLE HALLAM1, COURTNEY KIRBY1, OLIVIA LAHOTE1, SARAH H O'BRIEN1, 2, LYNDA VILLA-GOMEZ1, 2, AMY L. DUNN1, 2. 1Nationwide Children's Hospital Division of Pediatric Hematology, Oncology, Bone Marrow Transplant and Apheresis, Columbus, OH, USA. 2The Ohio State University College of Medicine, Columbus, OH, USA

11:45 - 12:45 PM
SATELLITE SYMPOSIUM
EXPLORING A SUBCUTANEOUS TREATMENT OPTION IN HEMOPHILIA CARE WITH HYMPAVZI (MARSTACIMAB-HNCQ) (SPONSORED BY PFIZER, INC. )
B115-116

Session will include a presentation on HYMPAVZI (marstacimab-hncq): the mechanism of action, key clinical trial data, administration guidelines, and patient cases followed by an audience Q&A. Speaker: Dr. Craig Kessler


GENE THERAPY IN HEMOPHILIA B: A JOURNEY OF INNOVATION AND IMPACT (SPONSORED BY CSL)
B113-114

Gene Therapy in Hemophilia B: A Journey of Innovation and Impact is a dynamic symposium hosted by leading hematology experts to investigate the evolution of gene therapy in hemophilia B, review five-year durability data from the HOPE-B trial, and share real-world clinical insights. This interactive session will also highlight a powerful patient story that brings the promise of gene therapy to life. This symposium provides an opportunity to deepen your understanding of transformative treatment approaches and explore considerations for the future for gene therapy in hemophilia B.



REAL-WORLD MANAGEMENT OF HEMOPHILIA A AND B: CLINICAL CASES WITH REBALANCING AND FACTOR REPLACEMENT THERAPIES (SPONSORED BY SANOFI)
B110-112

Join an interactive, poster-style session where leading experts present real-world patient cases managed with Sanofis portfolio of therapies for hemophilia A and B. Learn how personalized treatment strategies are applied in clinical practice from your peers.


12:45 - 1:30 PM
POSTERS/EXHIBITS/BREAK
POSTERS/EXHIBITS/BREAK (click to view)
Exhibit Hall A


A1. ANTICOAGULATION CLINICS


200
IMPORTANCE OF ANTICOAGULATION CLINICS IN IDENTIFICATION OF ANTIPHOSPHOLIPID ANTIBODY SYNDROME MISCLASSIFICATION
DEBORAH GILLARD1, LISA BAUMANN KREUZIGER1, 2, 3, JENNIFER HARDMAN1. 1Froedtert Health, Milwaukee, WI, USA. 2Medical College of Wisconsin, Milwaukee, WI, USA. 3Versiti Blood Research Institute, Milwaukee, WI, USA


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION


201
A RETROSPECTIVE US CLAIMS DATABASE STUDY ASSESSING TREATMENT PATTERNS AND BLEEDING EPISODES IN PATIENTS WITH PREVIOUSLY TREATED PRIMARY IMMUNE THROMBOCYTOPENIA
JOAO DA SILVA1, YU-CHEN YEH2, FIRAS DABBOUS3, CARLOS E BERTAGLIA GONCALVES4, SARAH HALE4, QIAN LI3, MEI LU4, SEAN SANA2, DOROTHY ROMANUS2. 1Thermo Fisher Scientific, Azores, Portugal. 2Takeda Development Center Americas, Inc, Cambridge, MA, USA. 3Thermo Fisher Scientific, Bethesda, MD, USA. 4Takeda Pharmaceuticals U. S. A, Inc, Lexington, MA, USA


202
HEPARIN INDUCED THROMBOCYTOPENIA IN ORTHOPEDIC SURGERY PATIENTS - A NATIONAL INPATIENTS SAMPLE DATABASE STUDY
SRUTHI/P RAMANAN1, KALAIVANI BABU2, SRINISHANT RAJARAJAN2, YIN YUE3, DEEP SHAH1. 1AHN Cancer Institute, Allegheny Health Network, Pittsburgh, PA, USA. 2Department of Internal Medicine, Allegheny Health Network, Pittsburgh, PA, USA. 3Allegheny Health Network, Pittsburgh, PA, USA


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS


203
TYPE 2N VON WILLEBRAND DISEASE IN PREGNANCY AND POSTPARTUM: A CASE REPORT
LAUREN N DURAND, ROBERT BONA. Yale University Dept of Medicine and Pediatrics, New Haven, CT, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


205
ASSAY PERFORMANCE AND HEAT-INACTIVATION CHALLENGES OF EFANESOCTOCOG ALFA IN FACTOR VIII ACTIVITY AND INHIBITOR TESTING
ERIN L AAKRE, MELISSA S STUART, JULIE I TANGE, JULIANA PEREZ BOTERO, RAJIV K PRUTHI. Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA


206
MAJOR ORTHOPEDIC SURGERIES CONDUCTED UNDER FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A AND B, WITH AND WITHOUT INHIBITORS
LARISSA BORNIKOVA1, LAURENT FRENZEL2, KAAN KAVAKLI3, LAISZLA³ NEMES4, STEPHANIE P'NG5, JING SUN6, CHUR-WOO YOU7, EZIO ZANON8, VANESSA SALINAS9, LAUREL A. MENAPACE10, SALIM KICHOU11, ABHIMANYU YARRAMANENI10, YUQIAN SHEN10, ALOK SRIVASTAVA12. 1Cancer Center, Massachusetts General Hospital, Boston, MA, USA. 2Groupe Hospitalier Necker Enfants Malades, Paris, France. 3Ege University Faculty of Medicine, Izmir, Turkey. 4Central Hospital of Northern Pest a, Budapest, Hungary. 5Fiona Stanley Hospital, Murdoch, Australia. 6Nanfang Hospital, Guangzhou, China. 7Eulji University Hospital, Daejeon, South Korea. 8Azienda Ospedale UniversitAn di Padova, Padua, Italy. 9Center for Inherited Blood, Disorders, Orange, CA, USA. 10Sanofi, Cambridge, MA, USA. 11Sanofi Genzyme, Paris, France. 12St. John's Medical College Hospital, Bengaluru, India


207
LIMITATION OF AUTOMATED VON WILLEBRAND TESTING IN IDENTIFYING A CASE OF ACQUIRED VON WILLEBRAND SYNDROME
SHANNON GOODALL, MAISSAA JANBAIN. Section of Hematology and Medical Oncology, Tulane School of Medicine, New Orleans, LA, USA


209
INCREASED LEVELS OF D-DIMER AND PLASMINOGEN ACTIVATOR INHIBITOR-1 IN IMMUNE THROMBOCYTOPENIA: IMPLICATIONS FOR THROMBOTIC COMPLICATIONS
KANNAN MEGANATHAN1, JEEVANATHAM. KAVIARASI1, CHITRALI L ROY1, RAVI RANJAN2, MANORANJAN MAHAPATRA2, RENU SAXENA2, JAWED FAREED3. 1Blood and Vascular Biology Research Lab, Department of Biotechnology, Central University of Tamil Nadu, Thiruvarur 610101. INDIA, Thiruvarur, India. 2Department of Hematology, All India Institute of Medical Sciences, New Delhi 110029. INDIA, New Delhi, India. 3Department of Molecular Pharmacology and Neuroscience, Loyola University Chicago IL 60153, USA, Chicago, IL, USA


211
INVESTIGATING THE EFFECT OF POPULATION PHARMACOKINETIC-GUIDED PDVWF/FVIII (1:1) PROPHYLAXIS FOR SEVERE VWD IN A REAL-WORLD SETTING: THE POPPK-WILPROPHY STUDY
ROBERT F. SIDONIO, JR. 1, RON A. A. MATHAAT2. 1Professor of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. 2Department of Hospital Pharmacy a Clinical Pharmacology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands


212
EVALUATING THE SAFETY AND TOLERABILITY OF SWITCHING FROM EMICIZUMAB TO FITUSIRAN PROPHYLAXIS IN MALES AGED ≥12 YEARS WITH SEVERE HEMOPHILIA A, WITH AND WITHOUT INHIBITORS: SWITCH STUDY
GUY YOUNG1, EKTA S CHHABRA2, SHARIQ ALI2, LILA-SABRINA FETITA3, MAREK DEMISSIE2, ABHIMANYU YARRAMANENI2, CHANCHALA KADDI2, SHENG C CHOU4. 1Childrena, Los Angeles, CA, USA. 2Sanofi, Cambridge, MA, USA. 3Sanofi Genzyme, Paris, France. 4Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan


A7. PATHOPHYSIOLOGY OF THROMBOSIS


213
EVALUATION OF BOVINE MUCOSAL HEPARINS USING PLASMA-BASED AND WHOLE BLOOD CLOTTING ASSAYS
TROY LABORE, BRENT CUDAL, MONICA PASTORIOUS, DEBRA HOPPENSTEADT, JAWED FAREED, WALTER JESKE, JEANINE WALENGA. Loyola University Chicago Department of Pathology and Laboratory Medicine, Chicago, IL, USA


A8. ANTITHROMBOTIC THERAPY


215
RETHINKING EXTENDED ANTICOAGULATION IN CANCER: IS LESS MORE? A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL TRIALS
URSULA MEDEIROS ARAUJO DE MATOS1, EDUARDO DAN ITAYA1, MOANA DIVINA DA SILVA SANTIAGO1, PATRICK FROELICH MELDOLA2, PEDRO L LAGE BODOUR DANIELIAN3, GUSTAVO J SILVA SANCHEZ1, SWARUP KUMAR4, RITIKA VANKINA4. 1Internal Medicine Department, University of Connecticut, Farmington, CT, USA. 2Federal University of Santa Catarina, School of Medicine, Santa Catarina, Brazil. 3Harvard T. H. Chan School of Public Health, Boston, MA, USA. 4Hematology and Oncology Department, University of Connecticut, Farmington, CT, USA


216
RISK FACTORS FOR SUPRATHERAPEUTIC APTTS ON HEPARIN INTRAVENOUS INFUSION
WADE TUNG, KATELYN SYLVESTER, KAITLIN CROWLEY, DAREEN KANAAN. Brigham and Women's Hospital, Boston, MA, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


217
EVALUATION OF UPDATED PROTOCOL FOR INTRAOPERATIVE ANTITHROMBIN-III AND UNFRACTIONATED HEPARIN ADMINISTRATION DURING CARDIAC SURGERY
RAZAN FANNOUN, STEPHANIE DAVIS, KATIE DANE, JOHN LINDSLEY, MARGARET BUCK, JESSICA CROW, PROMISE ARIYO. The Johns Hopkins Hospital, Baltimore, MD, USA


218
EVALUATION OF ANTITHROMBIN III UTILIZATION IN CARDIOVASCULAR SURGERY REQUIRING CARDIOPULMONARY BYPASS—A RETROSPECTIVE REVIEW OF INSTITUTIONAL PRACTICE
EKATERINA PECHENKO1, JEN OSBORN1, JOSH BREEDING2, VRUSHALI PACHPANDE1. 1M Health Fairview University of Minnesota Medical Center, Minneapolis, MN, USA. 2M Health Fairview Southdale Hospital, Edina, MN, USA


219
IMPLEMENTATION AND OUTCOMES OF A PHARMACIST-DRIVEN PROTOCOL FOR DIRECT THROMBIN INHIBITOR TITRATION IN PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA
AMBER L WOOLLEY, ANNE E ROSE. UW Health, Madison, WI, USA

1:30 - 3:00 PM
THROMBOSIS / LABORATORY
AUTOIMMUNE THROMBOSIS SYNDROMES
Chair/Organizer: Sabrina Racine-Brzostek, Leonardo Brandao
Oregon Ballroom 204


1:30
PF4 DISORDERS INCLUDING PEDIATRIC ISSUES
TED WARKENTIN.


2:00
IBD AND THROMBOSIS
ERIC BENCHIMOL.


2:30
ANTICOAGULANT MONITORING IN PATIENTS WITH APS--PRACTICAL CASE-BASED EXAMPLES
ANDY GOODWIN.

1:30 - 3:00 PM
BASIC SCIENCE
COAGULATION AT THE INTERSECTION OF INFLAMMATION AND INFECTION
Chair/Organizer: Bryce Kerlin, Kandace Gollomp
Oregon Ballroom 201


1:30
VWF & PLATELET REACTIVITY WITH INFLAMMATION AND INFECTION (DENGUE)
MARTHA EVA VIVEROS.


2:00
TRIAD OF PLATELETS, NETS, AND SEPSIS
KANDACE GOLLOMP.


2:30
INTERACTION OF PLATELETS AND VIRUSES
ED PRYZDIAL.

1:30 - 3:00 PM
HEMOSTASIS
LET'S GET THIS IRONED OUT (IMPACT OF UNTREATED BLEEDING IN WOMEN/GIRLS WITH BLEEDING DISORDERS)
Chair/Organizer: Julie Jaffray, Bethany Samuelson Bannow
Oregon Ballroom 203


1:30
IMPACT OF IRON DEFICIENCY AND ANEMIA
GLAIVY BATSULI.


2:00
APPROACHES TO TREATING WOMEN & GIRLS WITH BLEEDING DISORDERS
JULIE JAFFRAY.


2:30
THE DATA VACCUUM: WOMEN NOT INCLUDED IN CLINICAL TRIALS MEANS WE DON'T KNOW HOW THEIR HORMONES AFFECT CURRENT TREATMENTS FOR BLEEDING, WHAT IS MOST EFFICACIOUS FOR TYPES OF BLEEDING
DAWN ROTELLINI.

3:00 - 3:45 PM
POSTERS/EXHIBITS/BREAK
POSTERS/EXHIBITS/BREAK (click to view)
Exhibit Hall A


A1. ANTICOAGULATION CLINICS


300
ANTICOAGULATION STEWARDSHIP IN THE REAL-WORLD SETTING
NGHI HA, DENISE SUTTER-LONG, ANISA BICI, ERIN MOULAND, ELIZABETH RENNER. Michigan Medicine, Ann Arbor, MI, USA


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION


301
MODIFIED DURABLE PLATELET RESPONSE BY INTERNATIONAL WORKING GROUP CRITERIA: LUNA3 PHASE 3 STUDY OF RILZABRUTINIB VS PLACEBO IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA
WALEED GHANIMA1, YOSHITAKA MIYAKAWA2, NICHOLA COOPER3, MARIE LUISE HA¼TTER-KRAPNKE4, MARIA CRISTINA PASCUAL IZQUIERDO5, SYLVAIN AUDIA6, MEREDITH C. FOSTER7, MARIA BELEN RODRIGUEZ7, JING ZHAO7, AHMED DAAK7, DAVID J. KUTER8, DAVID FARBER7. 1A, Oslo, Norway. 2Department of Hematology, Saitama Medical University, Saitama, Japan. 3Hammersmith Hospital, London, United Kingdom. 4Department of Hematology, Oncology and Tumorimmunology, CharitAc - UniversitActsmedizin Berlin, Freie UniversitAct Berlin and Humboldt UniversitAct zu Berlin, Berlin, Germany. 5Department of Hematology, Gregorio MaraApon Hospital, Madrid, Spain. 6CHU Dijon Bourgogne - Hopital Francois Mitterrand, Dijon, France. 7Sanofi, Cambridge, MA, USA. 8Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA


302
IDENTIFICATION OF A PROPOSED NOVEL PATHOGENIC MYH-9 MUTATION IN A FAMILY WITH DUAL DIAGNOSIS OF VON WILLEBRAND DISEASE AND SUSPECTED MYH9-RELATED DISEASE
KAWANA SIMON1, RADHA VYAS1, COLLEEN CICCOSANTI2. 1Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. 2Division of Hematology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS


303
VALIDATION OF THE FIIX ASSAY ON WERFEN ACL TOP 750 ANALYZER
A ESHAGHPOUR1, K MOFFAT1, 2 , S CARLINO2, L LETERTRE3, E BELLEY-COTE1, D. M WITT4, B GUDMUNDSDOTTIR3, P ONUNDARSON3, 5, M CROWTHER1. 1Department of Medicine, McMaster University, Hamilton, ON, Canada. 2Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada. 3Departments of Medicine and Laboratory Medicine, Landspitali National University of Iceland, Reykjavik, Iceland. 4University of Utah College of Pharmacy, Salt Lake City, UT, USA. 5Faculty of Medicine, University of Iceland, Reyjkavik, Iceland


304
PERIOPERATIVE HEMOSTATIC STRATEGIES IN TOTAL KNEE ARTHROPLASTY FOR HEMOPHILIA: A SYSTEMATIC EVIDENCE REVIEW OF BLEEDING, FACTOR USE, AND THROMBOTIC RISK
JACK RUSSEK1, ANGAD THAKRAL2. 1Touro University California, Vallejo, CA, USA. 2Touro University California, Vallejo, CA, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


305
MAJOR DENTAL SURGERIES CONDUCTED UNDER FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A AND B, WITH AND WITHOUT INHIBITORS
SUCHITRA S ACHARYA1, LAURENT FRENZEL2, KAAN KAVAKLI3, TEH-LIANE KHOO4, LAISZLA³ NEMES5, JING SUN6, TE-FU WENG7, CHUR-WOO YOU8, SALIM KICHOU9, ABHIMANYU YARRAMANENI10, LAUREL A MENAPACE10, YUQIAN SHEN10, EZIO ZANON11. 1Northwell Health, New York, NY, USA. 2Groupe Hospitalier Necker Enfants Malades, Paris, France. 3Ege University Faculty of Medicine, Izmir, Turkey. 4Royal Prince Alfred Hospital, Sydney, Australia. 5Central Hospital of Northern Pest a, Budapest, Hungary. 6Nanfang Hospital, Guangzhou, China. 7Chung Shan Medical University Hospital, Taichung, Taiwan. 8Eulji University Hospital, Daejeon, South Korea. 9Sanofi Genzyme, Paris, France. 10Sanofi, Cambridge, MA, USA. 11Azienda Ospedale UniversitAn di Padova, Padua, Italy


306
CONCIZUMAB EFFICACY IN PATIENTS WITH HEMOPHILIA A/B WITHOUT INHIBITORS FROM THE PHASE 3 EXPLORER8 STUDY: A POST-HOC SENSITIVITY ANALYSIS FOR THE INTRA-PATIENT COMPARISON OF CONCIZUMAB WITH PREVIOUS PROPHYLAXIS
ANTHONY KC CHAN1, HERMANN EICHLER2, JULIEN BOVET3, RENACE BROWN FRANDSEN3, ALLISON P WHEELER4, EMILY WATERS5, PRATIMA CHOWDARY6, LEANDRA LEPORTE5. 1Department of Pediatrics, McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada. 2Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University and University Hospital, Homburg, Germany. 3Novo Nordisk A/S, SAcborg, Denmark. 4Division of Pediatric Hematology/Oncology a Division of Hematology and Oncology, University of Washington School of Medicine, Seattle, WA, USA. 5Novo Nordisk Inc, Plainsboro, NJ, USA. 6Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust, and Department of Haematology, Cancer Institute, University College London, London, United Kingdom


307
COMBINED FACTOR V AND FACTOR VIII DEFICIENCY ASSOCIATED WITH COMPOUND HETEROZYGOUS LMAN1 VARIANTS: A CASE REPORT
RIDA HAIDER 1, 2, NATALIE MONTANEZ1, 3, JOANNA LARSON1, 3, HARISH ESWARAN1, 4, MIGUEL ESCOBAR1, 4. 1Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA. 2University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Division of Medical Genetics, Houston, TX, USA. 3University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Division of Hematology, Houston, TX, USA. 4University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics and Internal Medicine, Division of Hematology, Houston, TX, USA


308
UPDATE ON A NOVEL INVESTIGATIONAL ADENO-ASSOCIATED VIRUS GENE THERAPY, SPK-8011QQ: RATIONALE AND DESIGN OF A PHASE IIB TRIAL
ANDREW D. LEAVITT1, ALICE COHEN2, M. ELAINE EYSTER3, KRISTINA HALEY4, AKSHAT JAIN5, DANIEL J. LEE6, MADDALENA MARCHESI7, CATHERINE MCGUINN8, NICOLAS RECEVEUR7, MICHAEL RECHT 9, AMIT SONI 10, SASHA SRECKOVIC11, MILES VILJANEN11. 1Departments of Medicine and of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA. 2Newark Beth Israel Medical Center, Newark, NJ, USA. 3Penn State Hershey Medical Center, Hershey, PA, USA. 4Hemostasis and Thrombosis Center, Oregon Health and Science University, Portland, OR, USA. 5Department of Pediatrics, Division of Hematology/Oncology, Loma Linda University School of Medicine, Loma Linda, CA, USA. 6Department of Hematology/Oncology, Kaiser Permanente, Vallejo/Vacaville, CA, USA. 7F. Hoffmann-La Roche Ltd, Basel, Switzerland. 8Department of Pediatrics, Weill Cornell Medicine College, New York, NY, USA. 9Hemophilia Treatment Center and Pediatric Hematology-Oncology, Yale University School of Medicine, New Haven, CT, USA. 10Center for Inherited Blood Disorders, Orange, CA, USA. 11Genentech, Inc, South San Francisco, CA, USA


309
APOLD1-ASSOCIATED VASCULAR-TYPE BLEEDING DISORDER PRESENTING WITH SEVERE POSTOPERATIVE HEMORRHAGE: A CASE REPORT
NATALIE MONTANEZ 1, 2, RIDA HAIDER 1, 3, JOANNA LARSON1, 2, HARISH ESWARAN1, 4, MIGUEL ESCOBAR1, 4. 1Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA. 2University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Division of Hematology, Houston, TX, USA. 3University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Division of Medical Genetics, Houston, TX, USA. 4University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics and Internal Medicine, Division of Hematology, Houston, TX, USA


310
SIXTH INTERIM ANALYSIS OF THE HEM-POWR STUDY: EVALUATING REAL-WORLD EFFECTIVENESS AND SAFETY OF DAMOCTOCOG ALFA PEGOL IN PATIENTS WITH SEVERE AND NONSEVERE HEMOPHILIA A IN THE UNITED STATES
MARK T REDING1, BENG FUH2, VANESSA SALINAS3, MAISSAA JANBAIN4. 1Center for Bleeding and Clotting Disorders, University of Minnesota, Minneapolis, MN, USA. 2East Carolina University, Greenville, NC, USA. 3Center for Inherited Blood Disorders, Orange, CA, USA. 4Tulane School of Medicine, New Orleans, LA, USA


311
BILIARY EVENTS IN THE FITUSIRAN CLINICAL DEVELOPMENT PROGRAM WITH THE ANTITHROMBIN-BASED DOSE REGIMEN
MINDY SIMPSON1, CANAN ALBAYRAK2, SAVITA RANGARAJAN3, 4, OLEKSANDRA STASYSHYN5, JING SUN6, CHUR-WOO YOU7, ABHIMANYU YARRAMANENI8, LAUREL A. MENAPACE8, YUQIAN SHEN8, KAAN KAVAKLI9. 1Rush Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL, USA. 2Ondokuz Mayis University Faculty of Medicine, Department of Pediatric Hematology, Samsun, Turkey. 3Advanced Centre for Oncology, Haematology and Rare Diseases, K. J. Somaiya Super Specialty Hospital, Mumbai, India. 4Faculty of Medicine, University of Southampton, Southampton, United Kingdom. 5Institute of Blood Pathology and Transfusion Medicine, Lviv. 6Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. 7Department of Pediatrics, Eulji University School of Medicine, Seoul, Korea. 8Sanofi, Cambridge, MA. 9Division of Hematology, Department of Pediatrics, Ege University Faculty of Medicine, Izmir, Turkey


312
THE ROLE OF VON WILLEBRAND FACTOR IN SICKLE CELL DISEASE CHRONIC ORGAN DAMAGE
MARTA WOLOSOWICZ1, TOMASZ KAMINSKI1, AYYANAR SIVANANTHAM1, NICHOLAS SWENDROWSKI1, NANDHINE RAJASEKHAR1, TIRTHADIPA PRADHAN-SUNDD1, 2. 1Versiti Blood Research Institute, Milwaukee, WI, USA. 2Medical College of Wisconsin, Wauwatosa, WI, USA


A7. PATHOPHYSIOLOGY OF THROMBOSIS


313
MOBILE PATIENTS MISS AND REFUSE MORE DOSES OF VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS
BRANDYN D. LAU1, 2, 3, 4, ERIK H. HOYER1, 2, DAURYNE L. SHAFFER5, PEGGY S. KRAUS5, ELLIOTT R. HAUT1, 2, 3, 4, MICHAEL B. STREIFF1, 2. 1Johns Hopkins School of Medicine, Baltimore, MD, USA. 2Armstrong Institute for Patient Safety and Quality, Baltimore, MD, USA. 3Welch Center for Prevention, Epidemiology, and Clinical Research, Baltimore, MD, USA. 4Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 5Johns Hopkins Hospital, Baltimore, MD, USA


A8. ANTITHROMBOTIC THERAPY


314
LOW RISK FOR MENINGOCOCCAL INFECTIONS WITH SYSTEMICALLY ADMINISTERED PEGCETACOPLAN, A COMPLEMENT C3 AND C3B INHIBITOR
CARLOS DE CASTRO1, SHEENA PATEL2, HOLLY SNYDER3, PETER HILLMEN3. 1Duke University, Durham, NC, USA. 2Swedish Orphan Biovitrum AB, Stockholm, Sweden. 3Apellis Pharmaceuticals, Inc, Waltham, MA, USA


315
APIXABAN VS RIVAROXABAN FOR VENOUS THROMBOEMBOLISM IN GASTROINTESTINAL CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
URSULA MEDEIROS ARAUJO DE MATOS1, PEDRO LUIZ LAGE BODOUR DANIELIAN2, MOANA DIVINA DA SILVA SANTIAGO1, NICOLE SEQUEIRA1. 1Internal Medicine Department, University of Connecticut, Farmington, CT, USA. 2Harvard T. H. Chan School of Public Health, Boston, MA, USA


316
MANAGEMENT AND OUTCOMES OF SUBTHERAPEUTIC WARFARIN ANTICOAGULATION IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME AND MECHANICAL MITRAL VALVES
SARA R VAZQUEZ1, 2, STEPHEN SHORT2, SPENCER GILBERT1, 2, DANIEL M WITT1, 2. 1University of Utah Health Thrombosis Service, Murray, UT, USA. 2University of Utah College of Pharmacy, Salt Lake City, UT, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


317
HEALTHCARE RESOURCE UTILIZATION IN PEOPLE WITH HEMOPHILIA TREATED WITHIN VS. EXTERNAL TO U. S. HEMOPHILIA TREATMENT CENTER NETWORK CLINICS: AN UPDATE FROM THE CHESS US STUDY
ENRICO FERRI GRAZZI1, MING LIM2, NICOLE CROOK3, MARIA SANTAELLA4, MICHAEL RECHT4, 5, ADAM GIERMASZ6, JONATHAN ROBERTS7, RANDALL CURTIS8. 1Federation of Hemophilia Associations (FedEmo), Milan, Italy. 2University of Utah, Salt Lake City, UT, USA. 3Center for Inherited Blood Disorders, Orange, CA, USA. 4National Bleeding Disorders Foundation, New York, NY, USA. 5Yale School of Medicine, New Haven, CT, USA. 6University of California, Davis, CA, USA. 7Bleeding a Clotting Disorders Institute, Peoria, IL, USA. 8Factor VIII Computing, Walnut Creek, CA, USA


318
HIGH STAKES HEMOSTASIS: DESCRIBING RISKS OF TRIPLE ANTITHROMBOTIC THERAPY IN PATIENTS ON TEMPORARY MECHANICAL CIRCULATORY SUPPORT
JOHN PURDIE, ERIC B. SIMPSON, ZACHARY R. SMITH, MIR B. BASIR, KRISTIN GRIEBE, BENJAMIN A. AUGUST. Henry Ford Hospital, Detroit, MI, USA

3:00 - 4:00 PM
POSTER SESSION
VIRTUAL POSTERS
Virtual Platform


ADEQUACY OF STANDARD THERAPEUTIC LOWMOLECULAR-WEIGHT HEPARIN DOSING IN PREGNANT WOMEN WITH PROSTHETIC HEART VALVES: AN ANTI-FACTOR XABASED EVALUATION (THSNATRAVEL AWARDEE)
TUSHAR SEHGAL1, K. APARNA SHARMA2, AMBUJ ROY3. 1Department of Laboratory Medicine, Delhi, India. 2Department of Obstetrics and Gynaecology, Delhi, India. 3Department of Cardiology, Delhi, India


DRUG-INDUCED THROMBOCYTOPENIA FROM PROTON PUMP INHIBITORS AND H BLOCKERS: A SYSTEMATIC REVIEW AND COMPARATIVE ANALYSIS OF PUBLISHED CASE REPORTS
SWAPNIL SURPUR, HIMANI MONGIA, SAMEER BHIMANI, MOHAMED AHMED, TEODOR LAZIC, JAMES CORTESE. The Wright Center for GME, Scranton, PA, USA


OPTIMIZING ANTICOAGULANT STRATEGIES IN PREGNANCY-ASSOCIATED HIT AND ACUTE STROKE IN A REAL-WORLD COMMUNITY SETTING
PEDROM FARID1, 2, 3, MARCO A HERRERA QUIJANO1, 2, 3, OMAR SAMARRAIE2, ANDREA CERVI1, 2, 3. 1Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. 2University of Windsor, Windsor, ON, Canada. 3Windsor Regional Hospital, Windsor, ON, Canada


TRENDS IN AGE-ADJUSTED MORTALITY RATES FOR DISSEMINATED INTRAVASCULAR COAGULATION IN SOLID AND HEMATOLOGIC CANCER PATIENTS: A 22-YEAR ANALYSIS OF UNITED STATES MORTALITY DATA BY SEX, RACE, AND GEOGRAPHIC REGION, 1999-2020.
JISS JOY1, RAHUL ANAND1, JOAN D. BECKMAN2. 1Department of Internal Medicine, The Guthrie Clinic, Robert Packer Hospital, Sayre, PA, USA. 2Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, USA


COMPARATIVE ANALYSIS OF CANCER-INDUCED VENOUS THROMBOEMBOLISM PREDICATORS AND RISK ASSESSMENT MODELS: A SYSTEMATIC REVIEW
TAREK A. ISSA1, NOOR A. HAYKAL1, YASMIN M. ELSAYED1, ISLAM A. ELJILANY2, HAZEM F. ELEWA1. 1College of Pharmacy, QU Health, Qatar University, Doha, Qatar. 2H. a, Tampa, FL, USA


COULD ELEVATED HOMOCYSTEINE BE A RISK FACTOR FOR CEREBRAL VENOUS THROMBOSIS?
NAWRIS ALHASSAN1, JAGDISH LAL2, SUSMIN KARKI3. 1Hope Clinic, Midvale, UT, USA. 2Burnaby Chronic Pain a Rehabilitation Clinic, Burnaby, BC, Canada. 3Institute of Medicine, Tribhuvan University, Maharajgunj, Nepal


VENOUS THROMBOEMBOLISM IN INTERNAL MEDICINE INPATIENTS: A ONE-YEAR PILOT STUDY OF PREVALENCE, PATIENT CHARACTERISTICS, AND SURVIVAL OUTCOMES FROM TURKEY.
BULENT KANTARCIOGLU1, 3, SULTAN GOZDE TEMIZ2, AYSE NILGUN KUL1, JAWED FAREED3, GULBUZ SEZGIN2. 1University of Health Sciences, Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital, Department of Internal Medicine, Division of Hematology, Istanbul, Turkey. 2University of Health Sciences, Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey. 3Loyola University Chicago, Department of Pathology a Laboratory Medicine, Cardiovascular Research Institute, Health Science Division, Maywood, IL, USA


DIAGNOSTIC PERFORMANCE OF THE KHORANA, ONKOTEV, AND PROTECHT SCORES FOR PREDICTING VENOUS THROMBOEMBOLISM IN OVARIAN CANCER
EMILIE MATHESON1, WESLEY CHORNEY1, RAHUL SINGH1, SUSAN O'SHEA1, 2. 1University College Cork, Cork, Ireland. 2Bons Secours Hospital, Cork, Ireland


INTERVENTIONAL THROMBOLYSIS VS ANTICOAGULATION ALONE FOR MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED ACUTE VENOUS THROMBOEMBOLISM: A REAL-WORLD PROPENSITY-MATCHED ANALYSIS
HASSAAN J. ABBASI1, DEVI PREETHAM R. VEERAMAGRI1, YASHAR HAGHIGHI1, PATRICK J. WILLARD2, CHRISTOPHER W. BAILEY3. 1Virginia Commonwealth University School of Medicine, Richmond, VA, USA. 2Department of Hematology-Oncology, VCU Health, Richmond, VA, USA. 3Division of Vascular Interventional Radiology, VCU Health, Richmond, VA, USA


TO CLOT OR NOT - RISK OF HOSPITAL-ACQUIRED VENOUS THROMBOEMBOLISM IN PATIENTS PRESCRIBED ASPIRIN AFTER TOTAL HIP ARTHROPLASTY/TOTAL KNEE ARTHROPLASTY
AMY N. CRUZ1, JOSH ROBERTS1, JEREMIAH DUBY1, JAMES CHHEN1, MICHELLE KRICHEVSKY2, TIFFANY PON1, 2. 1University of California Davis, Sacramento, CA, USA. 2University of California San Francisco, San Francisco, CA, USA


NOVEL THERAPEUTIC LIMITS CHRONIC INFLAMMATION IN ANIMAL MODELS OF CHRONIC INFLAMMATION.
P IVERSEN1, P KEMPAIAH2, G DORN2, E CAMPBELL2, Z KAKABADZE3, E RAMACCIOTTI4, J FAREED2. 1. Oregon State University, Corvallis, OR, USA. 2Loyola University Medical Center, Maywood, IL, USA. 3Tbilisi State Medical University, Tbilisi, Georgia. 4Science Valley Research Institute, Sao Paulo, Brazil


PARADOXICAL APIXABAN ANTI-XA LEVELS AFTER ANDEXANET ALFA: A CASE REPORT ON UNRELIABLE LABORATORY MONITORING AND EARLY THROMBOTIC RISK
SEAN TWARDY1, FARZEEN SYED2, SHELLEY KALSI2. 1Uniformed Services University of the Health Sciences, Bethesda, MD, USA. 2National Institutes of Health, Bethesda, MD, USA


IMPLEMENTING A STRUCTURED, MULTIDISCIPLINARY HOME INFUSION EDUCATION PROGRAM FOR PEDIATRIC BLEEDING DISORDERS
JULIE BASCONES, BRANDEN BERIA, AIMEE FOORD. Cure 4 the Kids Foundation, Las Vegas, NV, USA


IS PSEUDOTHROMBOCYTOPENIA ONLY A LABORATORY IN VITRO PHENOMENON?
MARIKA PIKTA1, 2, LAURA JOHANNA METTIS3, 4, MARIA KEERNIK5, KRISTI LEPIK6, KADRI SAKS6. 1Department of Laboratory Medicine, North Estonia Medical Centre, Tallinn, Estonia. 2Department of Health Technologies, Tallinn University of Technology, Tallinn, Estonia. 3Hematology Department, North Estonia Medical Centre, Tallinn, Estonia. 4University of Helsinki, Helsinki, Finland. 5Department of Laboratory Genetics, University of Tartu, Tartu, Estonia. 6Haematology Department, Tallinn Children`s Hospital, Tallinn, Estonia


DIAGNOSTIC LIMITATION OF MIXING STUDIES IN COAGULATION ASSAY
MARYAM POURABDOLLAH. University of Ottawa, OTTAWA, ON, Canada


AN UNUSUAL PRESENTATION OF MULTIPLE MYELOMA WITH SPONTANEOUS SUBARACHNOID HEMORRHAGE FROM SKULL BASE INVOLVEMENT AND THROMBOCYTOPENIA: CASE REPORT AND LITERATURE REVIEW
SWAPNIL SURPUR, SAMEER BHIMANI, IFUNANYA EKECHUKWU, TUSHAR ABHINAV, AADHYAA SHENOY, JAMES CORTESE. The Wright Center for GME, Scranton, PA, USA

3:45 - 5:15 PM
THROMBOSIS
ANTITHROMBOSIS STEWARDSHIP: HIGH-IMPACT OPPORTUNITIES TO OPTIMIZE CARE
Chair/Organizer: Allison Burnett, Anne Rose
Oregon Ballroom 203


3:45
OPTIMIZING ANTITHROMBOTIC OVERSIGHT: IMPROVING QUALITY AND SAFETY IN THROMBOSIS CARE
ARTHUR ALLEN.


4:15
THE CLINICAL PHARMACIST: IMPLEMENTATION OF ANTITHROMBOSIS STEWARDSHIP IN PERIOPERATIVE SETTING
TARA LECH.


4:45
THE ANTITHROMBOSIS PROVIDER CHAMPION: HIT AS A CASE STUDY
JORI MAY.

3:45 - 5:15 PM
BASIC SCIENCE
COAGULATION IN TISSUE-SPECIFIC INJURY AND REPAIR
Chair/Organizer: Glaivy Batsuli, Anandi Krishnan
Oregon Ballroom 201


3:45
ROLE OF FIBRINOGEN IN LIVER INJURY
LAUREN POOLE.


4:15
MITOCHONDRIAL CONTROL OF PROCOAGULANT PLATELETS IN VASCULAR INJURY AND REPAIR
JOE ASLAN.


4:45
PLATELETS IN WOUND HEALING
DANIELLE COENEN.

3:45 - 5:15 PM
HEMOSTASIS / LABORATORY
NEW THERAPEUTIC TARGETS FOR REBALANCED HEMOSTASIS: CLINICAL AND LABORATORY IMPLICATIONS
Chair/Organizer: Karen Moser, Kritin Maher
Oregon Ballroom 204


3:45
CLINICAL CONSIDERATIONS IN SELECTION OF NEWER HEMOPHILIA TREATMENTS
ANGELA WEYAND.


4:15
LABORATORY TESTING FOR PATIENTS ON EMICIZUMAB: CASE-BASED DISCUSSION AND COMMON CHALLENGES IN MONITORING
RAJIV PRUTHI.


4:45
LESSONS FROM CLINICAL TRIALS ON MONITORING ANTITHROMBIN ACTIVITY IN THE SETTING OF FITUSIRAN THERAPY
GUY YOUNG.

5:30 - 6:30 PM
SATELLITE SYMPOSIUM
BRIDGING THE GAPS: SCIENTIFIC UPDATES IN ITP, ITTP, AND WAIHA (SPONSORED BY SANOFI)
B113-114

Immune-mediated hematologic disordersincluding Immune Thrombocytopenic Purpura (ITP), warm Autoimmune Hemolytic Anemia (wAIHA), and immune Thrombotic Thrombocytopenic Purpura (iTTP)present significant diagnostic and therapeutic challenges in contemporary hematology practice. This symposium addresses the most recent updates in immune-mediated hematologic disorders.



RETHINKING HEMOPHILIA A MANAGEMENT: BALANCING BLEED PROTECTION AND ADMINISTRATION CONSIDERATIONS (SPONSORED BY NOVO NORDISK)
B115-116

Despite advancements in hemophilia A management, trade-offs remain: patients often choose between compromising bleed protection or accepting administration-related challenges. This program will reveal real-world data on these unspoken challenges and discuss strategies to identify barriers and enable more effective shared decision-making.